Experienced in Nevoid Basal Cell Carcinoma Syndrome

Gerold Schuler

Erlangen, BY, DE 
Experienced in Nevoid Basal Cell Carcinoma Syndrome
Erlangen, BY, DE 
OverviewLocationsClinical Research

Overview

Gerold Schuler practices in Erlangen, Germany. Mr. Schuler is rated as an Experienced expert by MediFind in the treatment of Nevoid Basal Cell Carcinoma Syndrome. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Merkel Cell Carcinoma.

His clinical research consists of co-authoring 119 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Nevoid Basal Cell Carcinoma Syndrome.

Gender
Male

Locations

Erlangen, BY, Germany
Other Locations
Alexander, NW, Germany
Giessen, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA
A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA
Enrollment Status: Unknown
Publish Date: December 02, 2022
Intervention Type: Biological
Study Drug: Autologous Dendritic Cells Loaded with Autologous Tumor RNA
Study Phase: Phase 3

119 Total Publications

Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schuler's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile